Bristol Myers to acquire Mirati Therapeutics for $58 per share 17:42 BMY Bristol Myers $56.66 / +0.24 (+0.43%) , MRTX Bristol Myers Squibb (BMY) and Mirati Therapeutics (MRTX) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8B.